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Abstract: Health care in Sub-Saharan Africa is being challenged by a double burden of disease 
as lifestyle diseases common in the developed world, such as stroke and atrial fibrillation (AF), 
increase, while, simultaneously, health issues of the developing world in terms of communi-
cable disease persist. The prevalence of AF is lower in Africa than in the developed world but 
is expected to increase significantly over the next few decades. Patients with AF in Africa tend 
to be younger and have a higher prevalence of rheumatic valvular heart disease than patients 
with AF in other regions. Permanent AF is the most prevalent type of AF in Africa, possibly 
due to the lower use of rhythm control strategies than in the developed world. Mortality rates 
of patients with AF in Africa are high, due largely to poor health care access and suboptimal 
therapy. The risk of stroke in AF, which is moderate to high in Africans as in the developed 
world, contributes to the high mortality rate. Patients with AF in Africa are often undertreated 
with antithrombotics, as cost and access to monitoring are major barriers. Vitamin K antagonists, 
including warfarin, are the most commonly available oral anticoagulants, but regular monitoring 
can be challenging, especially for patients in remote areas. Several non-vitamin K antagonist 
oral anticoagulants (NOACs) have been approved for use in countries across Sub-Saharan Africa 
and have the potential to reduce stroke burden. The higher cost of newer agents may be offset by 
the reduced need for regular monitoring, fixed dosing, and lower risk of intracranial bleeding; 
NOACs could provide a treatment option for patients in remote areas with limited access to 
regular monitoring. However, NOACs are not indicated in valvular AF. More work is needed to 
increase understanding of the epidemiology of AF and stroke, as well as to improve management 
strategies to reduce the burden of cardiovascular disease predicted for Africa.
Keywords: stroke, real-world treatment, treatment guidelines, barriers to care, non-vitamin K 
antagonist oral anticoagulants
Introduction
Economic and social changes in Sub-Saharan Africa are producing increased prosper-
ity, but unfortunately, they are also driving an epidemiological transition to a double 
burden of disease in the region.1,2 Health care systems in the developing world are chal-
lenged both by significant public health issues related to communicable disease and, 
increasingly, by a rising prevalence of noncommunicable lifestyle diseases, including 
obesity, tobacco addiction, hypertension, diabetes, and cardiovascular disease.2 Atrial 
fibrillation (AF) is the most common sustained cardiac arrhythmia in the developed 
world, and its prevalence in Africa is expected to grow as risk factors for AF, includ-
ing an aging population, increase in this region.3,4 Additionally, the large incidence 
of undertreated streptococcal infections in Africa contributes to the high burden of 
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valvular AF associated with rheumatic heart disease.5,6 The 
largest relative increase in cardiovascular disease burden 
between 1990 and 2010 in Sub-Saharan Africa was in AF.7 
It is estimated that by 2050, the prevalence of AF in Africa 
will be greater than in any other region of the world.8
The impact of AF on patients in Africa is not well 
characterized. However, it is important to increase awareness 
and understanding of AF in Africa for the future, as AF is a 
significant risk factor for stroke. Compared with stroke from 
other causes, a stroke associated with AF tends to be more 
disabling and carries a higher risk of death.9–11 Although the 
prevalence of stroke in Sub-Saharan Africa remains lower 
than in many developed countries, the burden of disease 
is high, with a high incidence of stroke-related mortality.12 
The leading cardiovascular cause of death and disability in 
2010 in Sub-Saharan Africa was stroke.7 Even in developed 
regions where high-quality health care is readily acces-
sible, patients with AF are undertreated with anticoagulant 
therapy;13,14 similarly, data indicate that patients with AF in 
Africa receive suboptimal antithrombotic treatment to reduce 
their risk of stroke.2,15 Additional attention and resources are 
needed for prevention and treatment of AF and its associated 
complications on the African continent and the developing 
world in general.
Epidemiology
Data on the prevalence and incidence of AF in Africa are 
sparse, but several small studies have been published since 
2010. A systematic review of AF epidemiology in developing 
regions suggested that the prevalence of AF in Africa cur-
rently is lower than in other regions studied.16 The reported 
prevalence of AF varies somewhat among studies and is 
expected to differ between hospital-based studies and in the 
general population, due at least in part to the patient selection 
in some hospitals being driven by factors such as afford-
ability and health care-seeking behavior. In a hospital-based 
study in South Africa, 4.6% of cardiology patients had AF, 
indicating an estimated prevalence of 5.6 cases per 100,000 
population per year.2 Similarly, in a retrospective chart 
review (N=3,908) at a cardiology institute in Ivory Coast, the 
prevalence of AF was 5.5% among patients admitted to the 
hospital over a 10-year period.17 In a retrospective study at a 
hospital in Senegal, the overall prevalence of AF was 5.4% 
and accounted for 66% of heart rhythm disorders.18 A lower 
prevalence rate of AF was reported in a Kenyan study in 
which the prevalence of AF and flutter in a tertiary referral 
hospital among medical patients was 0.7% (162/22,144); 
15% of these patients presented with a thromboembolic event 
(of patients with a thromboembolic event, 53% were of Asian 
or Caucasian origin).19 Among elderly residents ($70 years 
old) in a rural community in Tanzania, the crude prevalence 
rate of AF was strikingly low, at 0.7%.20 This estimate is much 
lower than the AF rates in elderly populations in the US or 
the European Union, where approximately 5% of people 
aged $65 years and 10% of people aged $80 years have 
been diagnosed with AF.21,22 The low rate of AF in African 
populations reported in some studies may be related to health 
care-seeking behavior and the fact that many patients do not 
have ready access to good health care. With increased access, 
it is likely that a higher prevalence of AF will be observed 
across Sub-Saharan Africa.
With regard to prevalence of AF among the African popu-
lation, it is notable that the prevalence and incidence of AF 
in the US is lower among African American men and women 
than in white men and women, even though risk factors for 
AF are more common among African Americans.23,24 These 
observations suggest that genetic factors may be contribut-
ing to a lower prevalence of AF in native Africans, but at 
this time, the contribution of genetic variants to a lower AF 
susceptibility in this population remains uncertain. It will be 
interesting to study whether environmental factors associated 
with increased urbanization and life expectancy in some parts 
of Sub-Saharan Africa will result, as predicted, in a higher 
AF burden in future years.
AF is independently associated with an increased risk of 
death.3 In the Framingham Heart Study, AF was associated 
with a 1.5- to 1.9-fold increase in mortality over 40 years of 
follow-up.25 In a study among a predominantly white popula-
tion in Olmsted County, MN, USA (mean age 73±14 years), 
the Kaplan–Meier estimates of survival at 4 months and 1 year 
after first AF diagnosis were 83% (95% confidence interval 
[CI]: 82%–85%) and 77% (95% CI: 76%–78%).26 Notably, 
among patients aged .70 years with electrocardiogram-
confirmed AF in rural Tanzania, the 1-year mortality rate 
was extremely high (50.0% in men and 66.6% in women).20 
Likewise, among an urban population with AF in Cameroon, 
the 1-year mortality rate after diagnosis was high (29.5%).15 
The lower reported prevalence of AF in Africa may also be 
related to higher mortality in patients with AF in that region, 
due to underdiagnosis and undertreatment in settings with 
limited health care resources.27
The pattern of AF can be classified as paroxysmal, per-
sistent, or permanent. Paroxysmal AF is self-terminating, 
usually within 48 hours, but may continue for up to 7 days. 
Persistent AF is present when an AF episode either lasts longer 
than 7 days or requires termination by  cardioversion, either 
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with drugs or by direct current cardioversion. Permanent 
AF is said to exist when the presence of the arrhythmia is 
accepted by the patient and physician. Notably, paroxysmal 
AF carries the same risk of stroke as permanent or persistent 
AF.11 With regard to these AF subtypes, permanent AF is the 
most prevalent type of AF among African individuals. In a 
prospective study of AF patients in Cameroon, the prevalence 
of paroxysmal, persistent, and permanent AF was 23%, 22%, 
and 56%, respectively.15 In a private, urban referral teaching 
hospital in East Africa, the distribution was paroxysmal 
AF 40%, persistent AF 13.5%, and permanent AF 40% 
(the remainder had incomplete follow-up data).19 African 
patients may progress more rapidly to permanent AF due to 
the reduced likelihood of detection when AF is paroxysmal 
and due to the less-frequent use of rhythm control therapies 
to restore and maintain sinus rhythm. Although some studies 
suggest that the permanent form of AF may be less common 
in the US and Europe (estimated prevalence of 30%–40%), 
other studies demonstrate that worldwide, permanent AF 
occurs in approximately 50% of patients, and the paroxysmal 
and persistent forms of AF occur in 25% each.28–31
Patients with AF have a greater risk of stroke than the 
general population; however, the stroke risk is heterogeneous, 
modulated significantly by patient comorbidities. A number of 
risk stratification measures have been developed to predict the 
risk of stroke among patients with AF. One of the most com-
monly used and well-validated methods is the CHADS
2
 score, 
which stratifies patients by history of Congestive heart failure, 
Hypertension, Age $75 years, Diabetes (one point for each), 
and Stroke or transient ischemic attack (two points).32 Patients 
with a CHADS
2
 score of zero are considered to be at lower 
risk of stroke; those with a score of one are considered to be 
at moderate risk, while those with a score $2 are considered 
to be at high risk.33,34 In a South African hospital-based study, 
the mean overall CHADS
2
 score of patients with AF (in 195 
nonrheumatic cases) was 1.5±0.9.2 In a study from a cardiac 
referral center in Cameroon, the mean CHADS
2
 score was 
1.9±0.1, and 92% of patients had a CHADS
2
 score $1.15 In a 
study based at the Cardiology Institute in Abidjan, Ivory Coast, 
47% of patients had a CHADS
2
 score of one or two, while 18% 
had a CHADS
2
 score $3.17 In the Kenya series mentioned pre-
viously, 65% of patients had a CHADS
2
 score .2.19 Similarly, 
in a European cohort, 20% of patients had a CHADS
2
 score of 
zero, 62% had a score of one or two, and 18% had a score $3.33 
Thus, similar to other regions of the world, most patients with 
AF in Africa are at moderate-to-high risk of stroke.
The CHA
2
DS
2
–VASc point scoring system is a modifica-
tion of CHADS
2
, which includes a larger number of risk factors 
(female sex, 65–74 years of age, and vascular disease) and has 
a broader score range (zero to nine). CHA
2
DS
2
–VASc (rather 
than CHADS
2
) has been given a Class I recommendation to 
assess stroke risk according to the 2012 European Society 
of Cardiology (ESC) and the 2014 American Heart Associa-
tion/American College of Cardiology/Heart Rhythm Society 
(AHA/ACC/HRS) AF Guidelines.35,36 CHA
2
DS
2
–VASc scores 
of zero and one are associated with adjusted stroke rates (per-
centage per year) of 0% and 1.3%, respectively, and a score of 
nine has a stroke rate of 15.2%.36 Notably in several studies, 
the CHA
2
DS
2
–VASc system discriminated stroke risk better 
among subjects with a baseline CHADS
2
 score of zero to one 
and defined anticoagulation recommendations more clearly 
than the CHADS
2
 score.35 However, because the CHA
2
DS
2
–
VASc scoring system has not been validated in the native 
African population, its utility in this setting currently remains 
uncertain and may be limited pending its validation.
Risk factors for AF
valvular AF
AF may be divided into two categories: valvular AF and 
nonvalvular AF (NVAF). Valvular AF can be defined as AF 
that occurs in association with a prosthetic heart valve, valve 
repair, or rheumatic valvular heart disease (predominantly 
mitral stenosis caused by prior streptococcal infection).36 
Rheumatic heart disease associated with valvular AF is much 
more common in Africa than in North America or Europe.2 
Among the regions enrolled in Randomized Evaluation of 
Long-Term Anticoagulation Therapy (RE-LY) AF, a global 
prospective registry that enrolled patients presenting to an 
emergency department with AF, rheumatic heart disease was 
present in 22% of African patients vs 2% of North American 
patients (Table 1). As a consequence of the higher prevalence 
Table 1 Selected risk factors for AF in African patients compared 
with the global population enrolled in a prospective registry of 
emergency department patients presenting with AF
Africa Overall
Number of patients with AF 1,137 15,400
Age, years, mean (SD) 57* (19) 66 (15)
Hypertension, % 54* 62
Previous stroke or TIA, % 14 14
Heart failure, % 64* 35
Diabetes mellitus, % 14* 22
Rheumatic heart disease, % 22* 2
CHADS2 score, mean 1.8 1.8
Notes: *Significantly different from the rest of the world (P,0.005). Data from 
Walker et al.37
Abbreviations: AF, atrial fibrillation; CHADS2, Congestive heart failure, Hyper-
tension, Age $75 years, and Diabetes (one point each), Stroke or transient ischemic 
attack (two points); SD, standard deviation; TIA, transient ischemic attack.
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of rheumatic heart disease, AF may affect people in Africa 
at a younger age than in the US or Europe. In RE-LY AF, 
Africa had the youngest median age of patients with AF 
(57.2 years, standard deviation [SD]: 18.8 for African patients 
vs 70.1 years, SD: 13.4 for North American patients).37
NvAF
Risk factors associated with NVAF include older age, hyper-
tension, diabetes, and heart disease.36 Several AF risk factors 
are prevalent among patients with AF in Africa. In a prospec-
tive study of AF patients in Cameroon, underlying cardiac dis-
orders, including hypertensive heart disease (48%), valvular 
heart disease (VHD; 26%), dilated cardiomyopathy (16%), 
and coronary artery disease (6%), were present in 156/172 
patients (91%).15 Similarly, a retrospective study of patients 
with AF in a teaching hospital in Kenya reported associated 
comorbidities, including hypertension (68%), heart failure 
(38%), diabetes mellitus (33%), and valvular abnormalities 
(12%).19 Among participants in the RE-LY AF registry, some 
risk factors for AF (older age, hypertension, and diabetes) 
were lower among Africans than in other regions of the world, 
but heart failure was much more common in Africans with 
AF (Table 1).37 The incidence of NVAF in Africa is likely 
to increase as rates of hypertension, diabetes, and other risk 
factors increase and the population ages.2
Burden of AF and stroke
AF is associated with an increased risk of stroke. Reported 
stroke prevalence varies throughout Africa, depending on the 
setting. In a 2007 study, the crude prevalence rate of stroke 
in urban Nigeria was 1.14/1,000, lower than the rates in most 
developed countries.38 In rural Nigeria, the crude prevalence 
of stroke was 1.63/1,000.39 For comparison, the prevalence 
of stroke among adult African Americans was 3.8% in 
2012.40 The lower prevalence in Nigeria may be related to 
lower incidence and higher stroke mortality compared with 
developed countries.
Although descriptive data are limited, patients with stroke 
in Africa are younger and have higher mortality than in other 
regions. In a single-center study of stroke patients in Ethiopia, 
the mean age of patients was 53.2 years and overall mortality 
was 44.5%.41 In this study, hypertension was the most frequent 
risk factor for stroke, followed by cardiac disease, observed 
in 66% and 23% of patients, respectively. Hypertension was 
undertreated, with most hypertensive patients receiving either 
no treatment (29%) or erratic and irregular treatments (38%). 
In another study from Kenya, the mean age for patients with 
stroke was 61 years, and  hypertension was found in 64%.42 
Valvular heart disease accounted for 40% of all heart disease, 
and almost half the patients with VHD also had AF, of whom 
none were on treatment.
Treatment options for AF management
Long-term anticoagulation is recommended to reduce the risk 
of stroke in patients with AF.34,36,43,44 The vitamin K antago-
nists (VKAs), including warfarin, are well-studied, having 
been used for many years, and low-cost generic versions are 
readily available. Warfarin is effective at reducing stroke risk 
in patients with AF, provided that good anticoagulation con-
trol is achieved by maintaining the international normalized 
ratio (INR) in the therapeutic range for at least 60%–70% of 
the time.45,46 A meta-analysis of six placebo-controlled trials 
showed that warfarin significantly reduced stroke risk by 64% 
and mortality by 26%.47 Use of warfarin, as in the case of all 
anticoagulants, carries some risk of bleeding. Administration 
of vitamin K can substantially reduce the effect of warfarin 
on INR in 24 hours, but because warfarin has a much longer 
duration of action than vitamin K, vitamin K may need 
to be readministered in patients with ongoing bleeding.48 
Alternatively, the effect of warfarin can be reversed more 
rapidly by administering fresh frozen plasma.49 Warfarin 
has a number of other limitations, including its slow onset 
and offset of action, food and drug interactions that require 
patients to be consistent in their dietary and alcohol intake, 
and a narrow therapeutic range that requires regular INR 
monitoring and dose adjustment to maintain anticoagulant 
levels within the therapeutic range.50
While warfarin remains the most commonly used oral 
anticoagulant in patients with AF, several non-vitamin K 
antagonist oral anticoagulants (NOACs), including dab-
igatran, rivaroxaban, apixaban, and edoxaban, have recently 
been approved to reduce the risk of stroke in patients with 
NVAF.51–54 Potential advantages of the NOACs relative to 
warfarin could be that they do not require routine INR or 
other anticoagulant level monitoring, they do not have food 
or drug interactions, and they can be prescribed in fixed 
doses. Disadvantages of the NOACs compared with warfarin 
include their cost and the current lack of a specific antidote. 
Furthermore, they are not indicated for stroke prevention 
in patients with valvular AF. The efficacy of these agents to 
reduce the risk of stroke in NVAF has been demonstrated in 
Phase III trials (Table 2).
In the RE-LY trial, patients with NVAF at moderate-to-
high risk of stroke were randomized to dabigatran (150 mg 
twice daily [bid] or 110 mg bid) or open-label warfarin. 
Both doses of dabigatran were noninferior to warfarin at 
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reducing stroke rates. Dabigatran 150 mg, but not 110 mg, 
was superior to warfarin. Rates of hemorrhagic stroke were 
significantly lower in both dabigatran arms than in the warfa-
rin arm. Major bleeding occurred significantly less frequently 
in the 110 mg dabigatran group and at similar rates in the 
warfarin and dabigatran 150 mg groups.55
In the Rivaroxaban Once Daily Oral Direct Factor Xa 
Inhibition Compared with Vitamin K Antagonism for Pre-
vention of Stroke and Embolism Trial in Atrial Fibrillation 
(ROCKET AF) trial, rivaroxaban was noninferior to warfarin 
for prevention of stroke and systemic embolism in patients 
with NVAF. There were no significant differences in the rates 
of major, as well as clinically relevant nonmajor, bleeding 
in patients taking rivaroxaban and warfarin. Intracranial 
hemorrhage and fatal bleeding occurred significantly less 
frequently with rivaroxaban, whereas gastrointestinal bleed-
ing, bleeding that led to a drop in the hemoglobin level, and 
bleeding that required transfusion occurred more frequently 
with rivaroxaban.
In the Apixaban for Reduction in Stroke and Other 
Thromboembolic Events in Atrial Fibrillation (ARISTO-
TLE) trial, which included patients with NVAF and at least 
one additional risk factor for stroke, apixaban 5 mg bid 
(2.5 mg bid in selected patients) significantly reduced the 
risk of stroke or systemic embolism, major bleeding, and 
mortality compared with warfarin (target INR: 2–3).56 In 
the Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent 
Stroke in Atrial Fibrillation Patients Who Have Failed or 
Are Unsuitable for Vitamin K Antagonist Treatment (AVER-
ROES) trial, apixaban 5.0 mg bid (2.5 mg bid in selected 
patients) provided significantly more protection from stroke 
and systemic embolism than aspirin 81–324 mg/day in 
patients with NVAF at increased risk of stroke, without 
significantly increasing major bleeding.57
In the Effective Anticoagulation with Factor Xa Next 
Generation in Atrial Fibrillation -Thrombolysis in Myocardial 
Infarction 48 (ENGAGE AF-TIMI 48) trial, patients with 
NVAF were randomized to edoxaban 60 mg daily, edoxaban 
30 mg daily, or warfarin (target INR: 2–3). Both once-daily 
regimens of edoxaban were noninferior to warfarin with 
respect to the prevention of stroke or systemic embolism, 
as well as being associated with significantly lower rates of 
bleeding and death from cardiovascular causes.58
Notably, a significant limitation of all the NOAC trials 
with regard to the use of these drugs in the African population 
is that none of the trials included a large number of patients 
from Africa, and the percentage of black subjects overall 
was small. Thus, the use of these newer agents compared 
with warfarin has not been well validated among subjects 
from the African continent. Furthermore, the percentage of 
patients with valvular (rheumatic) AF vs NVAF is expected 
to be higher in Africa than in some other regions of the world. 
The NOACs are not indicated in patients with significant 
VHD (including hemodynamically significant/severe mitral 
regurgitation or moderate-to-severe mitral or aortic valve 
stenosis) or in patients with prosthetic heart valves.
As noted earlier, an important drawback of warfarin is 
that patients require routine monitoring and dose adjustment 
to maintain serum levels in the therapeutic range.50 Access to 
monitoring may present a significant burden in some regions 
of Africa due to remote geographic locations or limited 
resources. Therefore, treatment with NOACs could minimize 
logistical hurdles for patients who lack access to laboratory 
services, as these drugs do not require routine monitoring; 
in the authors’ experience, people in remote areas opt to use 
NOACs instead of warfarin for this reason.
While the NOACs are widely available in Europe and the 
US, the approval status of these agents varies in the countries 
of Sub-Saharan Africa. The first NOAC approved for treat-
ment of NVAF in Africa was dabigatran, which received 
regulatory approval in Namibia in 2011.59 As of August 2014, 
rivaroxaban and dabigatran have been approved in Kenya;60 
rivaroxaban was the only NOAC approved in South Africa61 
and Nigeria;62 and none of the NOACs were available in 
Uganda63 or Zimbabwe.64 Up-to-date information about drug 
approvals in many countries in the Sub-Saharan region is 
difficult to obtain, and approvals are continuing; therefore, 
the list above may be incomplete.
AF stroke prevention treatment 
guidelines
Evidence-based guidelines published by national or regional 
medical associations provide physicians with recommenda-
tions on how to manage patients with NVAF (Table 3). 
The South African Stroke Society guidelines recommend 
primary stroke prevention for patients with AF stratified by 
CHADS
2
 risk score. Under these guidelines, patients with a 
CHADS
2
 score of zero may be treated with aspirin; for those 
with a CHADS
2
 score of one, warfarin or aspirin may be 
appropriate; and those with a CHADS
2
 score of $2 should 
receive warfarin.65 In addition to the CHADS
2
 score, physi-
cians should consider patient preference, bleeding risk, and 
access to reliable INR monitoring when making treatment 
decisions.
The ESC guidelines use the CHA
2
DS
2
–VASc score to 
predict stroke risk; the ESC recommends no treatment for 
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patients at low risk (CHA
2
DS
2
–VASc score of zero) and 
VKA or NOAC therapy for those at moderate-to-high risk 
(CHA
2
DS
2
–VASc score $1). In contrast to the South African 
guidelines, aspirin is recommended only for patients who 
refuse oral anticoagulant therapy.43
The National Institute for Health and Care Excellence 
(NICE) in the United Kingdom also stratifies patients by the 
CHA
2
DS
2
–VASc score. NICE advises that anticoagulation 
may be established with apixaban, dabigatran, rivaroxaban, 
or a VKA and recommends considering anticoagulation 
for men with a CHA
2
DS
2
–VASc score of one and offering 
anticoagulation to men and women with a CHA
2
DS
2
–VASc 
score $2. Bleeding risk should be taken into account, and 
the choice of anticoagulant should be based on the clinical 
features and preferences of the patient.66
In the absence of regional guidelines, physicians in 
Africa also have the option of referring to any of several dif-
ferent treatment guidelines published by US-based medical 
societies. The AHA and the American Stroke Association 
Scientific Advisory use the CHA
2
DS
2
–VASc score and rec-
ommend that it is reasonable to omit antithrombotic therapy 
for patients with a CHA
2
DS
2
–VASc score of zero; no anti-
thrombotic therapy, anticoagulant therapy, or aspirin therapy 
may be considered for patients with a CHA
2
DS
2
–VASc score 
of one; and oral anticoagulants are recommended for patients 
with a CHA
2
DS
2
–VASc score $2. Options include warfarin 
(INR: 2.0–3.0), dabigatran, apixaban, and rivaroxaban.67 The 
American College of Chest Physicians advises no therapy 
for patients with a CHADS
2
 score of zero and oral antico-
agulants for patients with CHADS
2
 score $1, with aspirin/
clopidogrel as an alternative for patients for whom oral 
anticoagulants are not appropriate.44 The ACC/AHA/HRS 
guidelines state that it is reasonable to omit antithrombotic 
therapy for patients with a CHA
2
DS
2
–VASc score of zero 
and suggest an oral anticoagulant or aspirin for patients 
with a CHA
2
DS
2
–VASc score of one. Oral anticoagulants 
(either warfarin or NOACs) are preferred for patients with 
CHA
2
DS
2
–VASc scores $2.36
Costs of AF and stroke
As in the rest of the world, both the costs associated with 
AF treatment and the costs of untreated AF are significant 
concerns in Africa. Indeed, given the paucity of resources 
available to much of the population of Africa, cost-effective 
management of AF is of paramount importance. Costs 
associated with AF may be related to anticoagulant therapy, 
Table 3 Guideline recommendations on the use of antithrombotic therapy for the prevention of stroke in patients with nonvalvular 
atrial fibrillation, based on stroke risk
Guideline CHADS2 risk score
0 1 $2
South African  
Stroke Society (2010)
Aspirin alone Warfarin or aspirin, taking into account  
patient preferences, bleeding risk, and  
access to reliable INR monitoring
Warfarin recommended, taking into 
account patient preferences, bleeding risk, 
and access to reliable INR monitoring
ACCP (2012) No antithrombotic  
therapy or aspirin  
alone
OAC suggested rather than no therapy  
or aspirin/aspirin + clopidogrel
OAC suggested rather than no therapy or 
aspirin/aspirin + clopidogrel
If OAC unsuitable or not desired,  
aspirin + clopidogrel suggested rather  
than aspirin alone
If OAC unsuitable or not desired, aspirin +  
clopidogrel suggested rather than aspirin 
alone
Guideline CHA2DS2–VASc risk score
0 1 $2
ESC (2012) No antithrombotic  
therapy
Consider OAC, depending on individual  
risk (not recommended in female  
patients aged ,65 years with lone AF)
NOAC (dabigatran, rivaroxaban, and 
apixaban) or VKA recommended. If patient 
refuses OAC, consider aspirin + clopidogrel
NICE (2014) No OAC  
recommended
Consider OAC for men, taking into  
account bleeding risk and individual  
patient risks and preferences
OAC recommended, taking into account 
bleeding risk and individual patient risks and 
preferences
ACC/AHA/HRS  
(2014)
Reasonable to omit  
antithrombotic therapy
Either no therapy or consider aspirin  
or OAC
OAC recommended, either warfarin  
(INR 2–3) or NOAC
ASA/AHA  
(2014)
Reasonable to omit  
antithrombotic therapy
No antithrombotic therapy,  
anticoagulant therapy, or aspirin  
therapy may be considered
OAC recommended, either warfarin  
(INR 2–3) or NOAC
Abbreviations: ACC/AHA/HRS, American College of Cardiology/American Heart Association/Heart Rhythm Society; ACCP, American College of Chest Physicians; 
AF, atrial fibrillation; ASA, American Stroke Association; CHADS2, Congestive heart failure, Hypertension, Age $75 years, Diabetes (one point each), Stroke or transient 
ischemic attack (two points); ESC, European Society of Cardiology; INR, international normalized ratio; NICE, National Institute for Health and Care Excellence; 
NOAC, non-vitamin K antagonist oral anticoagulants; OAC, oral anticoagulant; VKA, vitamin K antagonist.
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INR monitoring, or treatment of AF-related stroke. Failure 
to maintain optimal anticoagulation places patients at risk 
of complications, including both stroke and bleeding, the 
management of which involves a significant cost.68 A chart 
review of stroke patients in Nigeria revealed that patients 
require an average of US$600 and $4,860 (direct costs only) 
in a government and a private hospital, respectively, to access 
care within the first 36 weeks poststroke.69 Average income in 
Nigeria is ,$2/day, which suggests that managing stroke con-
stitutes a huge direct cost burden unaffordable by an average 
Nigerian stroke sufferer.69 Cost-effectiveness studies for the 
region are limited; however, one study in the South African 
private sector indicated that compared with warfarin, dabiga-
tran as first-line treatment was cost effective in reducing the 
risk of stroke in patients with AF when used in accordance 
with its registered indication. While the costs of dabigatran 
were estimated to be higher than those for warfarin (Rands 
[R] 60,365 vs R24,243, respectively), the costs of clinical 
events and follow-up costs were estimated to be lower than for 
warfarin (R23,246 vs R24,888 and R236,496 vs R252,229, 
respectively).70
Although NOACs are available in certain parts of Africa, 
the drug costs of the NOACs make them unaffordable for 
many patients. Because generic warfarin is available at 
lower cost, warfarin and other VKAs are likely to remain 
the standard of care in the region.71 Notably, however, as 
prosperity in Africa (measured as the proportion of the 
population living above the poverty line) increases,72 the 
African middle class may find the convenience of NOACs, 
with their reduced burden of monitoring and fewer food–
drug interactions, preferable to warfarin irrespective of their 
drug-related costs.
Real-world treatment with anticoagulants 
for stroke prevention
Several studies have demonstrated wide variability in the use 
of anticoagulant therapy in clinical practice in Africa, prob-
ably related to regional differences in access to medical care 
across the African continent. In general, treatment patterns 
differ between rural and urban settings, with urban patients 
more likely to receive anticoagulants. One study noted that 
urban patients were more likely to have a relative contraindi-
cation to antithrombotic therapy than rural patients (24% vs 
10%; P=0.028) but received antithrombotic therapy more 
often (38% vs 19%; P=0.025).73 In a prospective study of 
AF patients in Cameroon between 2006 and 2007, in patients 
with an indication for oral anticoagulation, only 34% (54 of 
158) actually received it.15 Similarly, in a hospital-based 
study from Soweto, South Africa, between 2006 and 2008, 
33% of patients with AF received warfarin.2 In contrast, 
a much higher percentage of patients received an antico-
agulant in Senegal, where in a retrospective hospital-based 
study between 2003 and 2007, anticoagulation by VKA was 
established in 62% of cases.18 Access to quality health care 
may be getting better in some parts of Africa with improving 
economic and social conditions. A study at a private urban 
referral teaching hospital in Nairobi, Kenya, found that 
80% of patients with AF and a CHADS
2
 score $2 received 
anticoagulation between 2008 and 2010.19 Similarly, a recent 
observational multicenter national registry in South Africa 
indicated that 75% of patients with AF were on warfarin for 
stroke prevention in 2010 and 2011.74
Among patients who receive anticoagulant therapy, INR 
control varies greatly. In a post hoc analysis of Atrial fibril-
lation Clopidogrel Trial with Irbesartan for prevention of 
Vascular Events -Warfarin arm (ACTIVE-W), a randomized 
prospective trial comparing VKA therapy with clopidogrel 
plus aspirin, patients from South Africa randomized to 
VKA therapy (n=98) achieved poor INR control, with the 
lowest time in therapeutic range (TTR) of any country in 
the trial.45,75 Patients from South Africa had a mean TTR 
of 46%, vs 63% for the study population as a whole.45 In 
contrast, in ROCKET-AF, the median individual TTR for 
South African patients on warfarin was similar to that of 
the study population as a whole (55% for each group).76 In 
ARISTOTLE, the median TTR for patients on warfarin was 
approximately 68% for patients in South Africa, vs a median 
of 66% (52%–77%) for the study population as a whole.77 
However, TTR for patients enrolled in randomized controlled 
clinical trials may not provide an accurate reflection of TTR 
for patients treated in clinical practice. Among the regions 
enrolled in the RE-LY AF registry, TTR was lower in Africa 
than in Europe or North America.37 In a multicenter study 
in South Africa, although all the patients were maintained 
above the minimum INR value of 2.0, approximately 50% 
had at least one record of INR above the cut-off value of 3.5, 
possibly reflecting barriers of cost and access that may be 
especially problematic for rural patients.78
Observational studies have begun assessing the impact, 
safety, and efficacy of the NOACs for stroke prevention in 
AF in routine clinical practice around the world. It will be of 
interest to understand how these novel treatments are being 
used in the real-world clinical setting. Global Registry on 
Long-Term Oral Antithrombotic Treatment in Patients with 
Atrial Fibrillation (GLORIA-AF) is a large multinational 
prospective registry designed to characterize the treatment 
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of patients newly diagnosed with NVAF who are at risk of 
stroke and who are being treated with warfarin, aspirin, and 
NOACs; GLORIA-AF should provide important real-world 
information on antithrombotic-prescribing patterns and 
patient outcomes. It is vital to analyze whether the safety-
and-efficacy profile of NOACs established in the clinical trials 
is also observed in routine clinical practice. In this regard, 
Xarelto® (Janssen Pharmaceuticals, Inc., Titusville, NJ, 
USA) for Prevention of Stroke in Patients with Nonvalvular 
Atrial Fibrillation, Eastern Europe, Middle East, Africa, and 
Latin America (XANTUS-EL) is evaluating rivaroxaban. 
GLORIA-AF and XANTUS-EL will include South African 
and Kenyan sites, respectively. Similarly, the ongoing Global 
Anticoagulant Registry in the FIELD-Atrial Fibrillation 
(GARFIELD-AF) international observational prospective 
study aims to investigate real-life treatment patterns and 
patient outcomes, and it includes South African sites.79,80
Rate control vs rhythm control in AF
Although stroke prevention is a critically important therapeu-
tic goal in AF patients, management of AF patients is also 
aimed at reducing symptoms and preventing other complica-
tions associated with AF by control of the ventricular rate and 
correction of the rhythm disturbance. Rate control appears 
to be the preferred treatment strategy relative to rhythm 
control for AF management among most clinicians treating 
patients with AF in Africa. At a private referral hospital in 
Nairobi, rate control, using a mixture of digoxin, beta-
blockers, calcium channel blockers, and amiodarone, alone 
and in combination, was the preferred strategy for arrhythmia 
management in 78% of patients.19 A national observational 
registry in South Africa found that rate control, mainly 
with beta-blockers, was pursued in 64% of AF patients.74 
A prospective study involving ten cardiologists in Cameroon 
treating AF found that a rate control strategy using digoxin 
and amiodarone was chosen in 84% of patients.15 Consistent 
with these observations, a study that assessed pharmacologi-
cal management of AF in developing countries around the 
world found a high prevalence of rate control therapy use 
(55%–87%).16 This treatment approach contrasts with AF 
management in developed countries, where physicians gen-
erally prefer rhythm control over rate control strategies. The 
REgistry on Cardiac rhythm disORDers assessing the control 
of Atrial Fibrillation (RecordAF) observational study of AF 
management among recently diagnosed patients in Europe, 
America, and Asia reported that rhythm control was applied 
to 55% of patients, whereas rate control was selected in 45% 
of patients at baseline.81 Similarly, in the Euro Heart Survey, 
67% of symptomatic patients with AF were managed with a 
rhythm control approach.28
Barriers to evidence-based health care in patients 
with AF
While the provision of good health care at low cost is an 
extremely complex undertaking, countries such as Ethiopia 
have substantially improved their health care systems in 
recent years, and their success points to factors that may 
affect the ability of other countries to improve.82 Factors 
that influenced success included political commitment, 
effective bureaucracies, and the ability to innovate and adapt 
to resource limitations.82
In Sub-Saharan Africa, the leading cardiovascular cause 
of death and disability is stroke, and cardiovascular deaths 
occur at younger ages than in the rest of the world.7 Rates 
of stroke-related disability and mortality are ten fold higher 
in medically underserved regions of the world compared 
with the most developed nations.83 This is primarily due to 
the lack of access to primary care to screen for and mitigate 
stroke risk factors.83 In the developed world, AF is the lead-
ing preventable cause of stroke, accounting for 15%–20% 
of all strokes.84 Therefore, effective strategies to reduce the 
risk of stroke in patients with AF must be considered in the 
context of local health care systems.
A recent proof-of-concept study in Ethiopia and 
Swaziland adapted tools and systems originally developed for 
long-term routine care of patients with HIV to treat patients 
with noncommunicable diseases using diabetes mellitus, 
another condition requiring ongoing monitoring and care, 
as a test case.85 The study demonstrated the potential to 
rapidly improve the quality of care for diabetes by adapting 
HIV-specific policies, systems, and tools.85 This approach 
could potentially be expanded to other noncommunicable 
conditions, such as AF.
Summary and conclusion
Although infectious disease has historically been a greater 
health concern in Africa, noncommunicable disease, including 
AF and stroke, is a growing issue in a setting where resources 
and access to health care are extremely limited for a large 
portion of the population. Data on epidemiology of AF in 
Africa are scarce. The available information suggests a lower 
prevalence of diagnosed AF currently in Sub-Saharan Africa, 
but the prevalence of AF in this region is expected to grow 
significantly over the next 2–3 decades. When AF is detected 
in Africa, it is more likely to be permanent and associated with 
high morbidity and mortality. Patients with AF in Africa are 
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much more likely to be treated with rate control rather than 
rhythm control in comparison with patients in Europe or the 
US. Valvular AF is much more common in Africa than in 
Europe or the US due to the high burden of rheumatic heart 
disease. Warfarin or the NOACs are treatment options for 
stroke prevention in NVAF, whereas the NOACs are not indi-
cated for treatment of valvular AF. While undertreatment of 
AF remains a worldwide problem, patients with AF in Africa 
are even more likely to be undertreated than those in other 
regions due to major differences in the availability of health 
care resources and socioeconomic conditions. In most of 
Africa, fewer patients with AF receive anticoagulant therapy 
compared with those in other parts of the world. In addition, 
some studies suggest that those receiving treatment may have 
shorter times in the therapeutic range while receiving warfarin. 
Although the overall prevalence of stroke in Africa is low 
compared with that in the developed world, possibly due to 
the younger age of the region’s population, AF is a leading 
preventable cause of stroke. Undertreatment of AF patients 
with antithrombotic therapy leaves patients at increased risk 
of stroke. Furthermore, morbidity and mortality associated 
with AF-related stroke is significant. NOACs are starting to 
become available around Africa, and as availability increases, 
health care providers in Africa will have new treatment 
options to manage NVAF and reduce the risk of stroke in their 
patients. More studies and resources are needed to improve 
understanding of the epidemiology and management of AF 
in Sub-Saharan Africa.
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